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I.

Intro
In 2010, Congress passed the Patient Protection and Affordable Care Act (PPACA)

which created an individual mandate for every American to carry health insurance or face
financial penalties. The end result is the single largest increase in the number of insured
Americans since the creation of Medicare under Lyndon B Johnson’s Great Society
Program.1 The drafters of PPACA emphasized three main objectives: 1) to provide access
to healthcare to all; 2) to improve quality of care; and 3) to find ways to slow or reduce the
cost of care.

2

In expanding healthcare coverage to more than 30 million Americans

currently without insurance, the act will guarantee that many who need medical care will
not be left hanging. 3
However, after the Supreme Court’s recent ruling upholding the key components of
PPACA the mere validation of the healthcare bill has hardly ended the debate. Healthcare
organizations face a unique and wide-ranging set of challenges as a result of this

1

Ben Shepherd, A new Focus: How to Profit from Healthcare Reform, Investing Daily (January 14, 2013), available
at http://www.investingdaily.com/16082/a-new-focus-how-to-profit-from-healthcare-reform
2
Ron Rimkus, The economics of Obamacare: The implications for Healthcare Investing, Enterprising Investor (July
11, 2012), available at http://blogs.cfainstitute.org/investor/2012/07/11/the-economics-of-obamacare-theimplications-for-healthcare-investing/
3
The Lurking Danger in the Affordable Care Act, Daily Finance (October 2, 2012), available at
www.dailyfinance.com/2012/10/02/the-lurking-danger-in-the-affordable-care-act/
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legislation, from payment to reimbursement reform.4 These changes, regardless of whether
critics are in favor or against the reform, will have a drastic effect outside the healthcare
market.

PPACA will affect employment practices, tax considerations and the way

individuals and firms invest their money. 5 One of the controversial provisions in the
healthcare reform bill, which will have these cross market effects, is the new tax on
medical device sales. This new 2.3% tax on the United States sale of medical devices
began in January 2013. 6 This tax will be assessed on revenues of the devices not solely
profits.7 On top of federal, state and local taxes companies in 2013 are anticipating to pay
approximately 50 percent of every dollar earned. 8
With the healthcare industry becoming an integral part of the United States
economy; it will be critical for investors to maintain exposure to the changes they face with
the implementation of PPACA in order for them to enjoy robust gains, sustain a solid
footing in the healthcare industry and maintain a diversified portfolio. This paper will
focus on the public policy implication of policy makers need to be conscious of market
trends and Wall Street perceptions when determining the full effect of their legislation. Part
2 of the paper will discuss the projected effects of the implementation on PPACA on the
healthcare industry.

Specifically, this paper will focus on how investors, brokers and

investment firms will be affected by the new Medical Loss Ratios (MLR) regulations on

4

Affordable Care Act Update: Implementing Medicare Cost Saving, CMS Office of the Actuary (June 8, 2010),
available at http://www.cms.gov/apps/docs/aca-update-implementing-medicare-costs-savings.pdf
5
Jim Blankenship, What Obamacare Will Do to Your Taxes, Forbes (July 9, 2012), available at
http://www.forbes.com/sites/advisor/2012/07/09/what-obamacare-will-do-to-your-taxes/
6
Just the Facts: The Medical Device Excise Tax, MedReps.com(Last Visited February, 27 2013), available at
http://www.medreps.com/medical-sales-careers/medical-device-excise-tax/
7
Ruth Hoffman, KPMG TaxWatch Recap: New Medical Device Excise Tax, KPMG (2012), available at
http://www.us.kpmg.com/microsite/taxnewsflash/2012/Jan/Excise.v5_web.pdf. The tax is levied against medical
device manufacturer’s revenues regardless of whether the manufacturer has a profit.
8
Devon Herrick, The Job-Killing Medical Device Tax, National Center for Policy Analysis (February 2012), Issue
Brief No. 106, http://www.ncpa.org/pdfs/ib106.pdf
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issuers, formation of Accountable Care Organizations (ACOs) and the new tax on medical
devices. These new implications will have a direct effect on their corresponding markets,
for instance; Formation of ACOs will affect the way hospitals operate, medical device
manufacturers will have to adapt to the way medical devices are developed and sold and
MLR regulations will impact how issuers price their products and the quality of service.
However, with the passage of the Affordable Care Act (“ACA”) still in its infancy the full
effect of these provisions are only mere speculations.
This uncertainty has led analysts looking to invest in the healthcare industry to
project how hospitals, doctors and medical manufactures will react to these new ACA
regulations. One particular area of interest is venture capitalist contributions and medical
technology Initial Public Offerings. Initial indications express decreasing confidence in
the upcoming years in these areas and project less funding of research and development as
well as advancement of startup companies.

9

Considering the projections from several

conflicting analysts as to their anticipated effects on the overall market response to this
legislation, these opinions will assist us in understanding how investors gain or lose
confidence in an investment opportunity based on how other perceive the rate of return and
market stability. While one sub-sector of the healthcare industry see continuous growth and
revenue, others might discover increased costs due to the need to conform to the new ACA
standards coupled with a decreased influx of available capital contributions.

9

Scott Gottlieb, Healthcare consolidation and Competition after PPACA, American Enterprise Institute (May 18,
2012), http://www.aei.org/speech/health/healthcare-reform/ppaca/health-care-consolidation-and-competition-afterppaca/ ; see also Allison Bell, Hearing Witness: PPACA Is Scaring Capital Away from Health Services, Life
Health Pro (May 18, 2012) http://www.lifehealthpro.com/2012/05/18/hearing-witness-ppaca-is-scaring-capitalaway-from (discussing the differing views of Scott Gottlieb and Thomas Greaney regarding incentives to invest
capital)

3

Part 3 of this article will provide a brief overview on how analysts and investors
determine and assess investment potential value through quantitative analysis. Quantitative
analysis is a financial analysis technique that seeks to understand behavior by using
complex mathematical and statistical modeling, measurement and research. 10 These types
of financial breakdowns can be done for a number of reasons such as measurement,
performance evaluation or valuation of a financial instrument. 11 It can also be used to
predict real world events such as changes in a share price or to ascertain investment
quality. 12 In general, during economic downturns investors need to track pricing and
premium levels, medical costs and member growth over time, as well as the regulato ry
noise related to covered charges through the government health programs . Part 3 will
further discuss how analysts apply quantitative analysis to assess the value of healthcare
industry investment opportunities. Predominantly, this area will focus on projection
analysis and financial ratios investors rely on such as Medical Cost Ratio. 13 In addition,
investors utilize market data such as the S&P Healthcare Sector Index and return on
investment breakdowns. Although quantitative analysis is a powerful tool for evaluating
investments, it rarely tells a complete story without complementary qualitative analysis.
This article will also discuss other statistics used by investors to obtain an optimal portfolio
within the healthcare context.
Part 4 of this article discuss the detachment of policy makers within the health care
industry who do not appreciate the fragility and instability of capital markets as a result of
10

Campbell R. Harvey, Quantitative Analysis, Hyper textual Financial Glossary, available at
http://people.duke.edu/~charvey/Classes/wpg/bfglosq.htm
11
Understanding Financial Statements, Dun & Bradstreet (Last Visited April 10, 2013), available at
http://www.dnb.com/customer-service/understanding-financial-statements.html
12
Id.
13
Robert Kohut, UnitedHealth Investors: Buy, Sell or Hold?, Wall St. Cheat Sheet (October 27, 2012), available at
http://wallstcheatsheet.com/stocks/unitedhealth-investors-buy-sell-or-hold.html/
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the policies they legislate. Using the information gathered by quantitative analytics many
investors and analysts project trends of investing in the healthcare sector based on this
information.14 In a theory developed by John Maynard Keynes to explain price fluctuations
in markets, Keynes believed “investors are not looking only at fundamental values, but
rather on what they think everyone else thinks their value is, or what everybody else would
predict the average assessment of value to be.”15 Despite some reports focused on the
opportunity growth and potential investment return for the healthcare industry, others see a
shrinking market for investment in companies within the early stages of development, in
particular the medical device sector. Ultimately, as the market responses to the changes in
the healthcare sector the medical device tax may only hurt patient care and exacerbate
current trends of reduced utilization of medical devices. We may learn that the effect of
the Affordable Care Act not only affects the regulatory facet of health care but also the
economic landscape of health care. Artificially capping profits in the health sector may
mean that venture capitalists and investment firms will find themselves in a position where
it is no longer profitable to add healthcare companies to their portfolios.16 This could
result in an exodus of capital funding, jobs, and new innovation.

14

Suzanne McGee, Obamacare Ruling: Tricky Investing Terrain, MSN Money (June 29, 2012), available at
http://money.msn.com/top-stocks/post.aspx?post=2d91f7e6-4ff1-4327-ac83-f27b0fdb317f
15
Robert J. Shiller, The Beauty Contest That’s Shaking Wall St., The New York Times (September 3, 2011),
available at http://www.nytimes.com/2011/09/04/business/economy/on-wall-st-a-keynesian-beautycontest.html?_r=0
16
Frank Pasquale, Joining or Changing The Conversation: Catholic Social Thought and Intellectual Property,
Cardozo Arts & Entertainment, Vol. 29:681 p. 687. “Other unintended consequences could emerge. Compulsory
licensing of essential drugs could lead to a diversion of more resources to research on nonessential drugs. No one is
pushing for compulsory licensing for baldness cures or pet medications. In 2008, the purchasing power of the
average American dog was higher than that of forty percent of the world’s population”
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II.

Implementation of the Affordable Care Act
a. ACO’s
ACOs are collaborations that integrate groups of providers formed from a variety of

entities. These include physicians (particularly primary care physicians), individual
physicians, hospitals, partnerships and others forms of joint-ventures. 17 These providers
work to manage and coordinate care for Medicare and commercial beneficiaries.

A

common feature of successful ACOs will be its ability to connect and synchronize the
interests of the providers, payers and patients. 18 In doing so, these ACOs may receive
shared-saving bonuses from a payer by achieving measured quality targets and
demonstrating real reductions in overall spending growth for a defined population of
patients19
The majority of ACO proposals assume that providers within each community will
come together to form these integrated delivery models and solicit other providers in the
community to voluntarily join the ACO. 20 ACOs aim to change both the philosophy and
practice patterns of providers and in turn benefit all patients from the delivery of higher-

17

Timony K. Lake, Kate A. Stewart and Paul B. Ginsburg, Lessons from the Field: Making ACOs Real, National
Institute for Health Care Reform, No.2 (Jan. 2011)
18
Elizabeth G. Litten. “ACOs: Getting More for Less?” New Jersey Law Journal Vol. 204- No. 8 (May 23, 2011)
available at http://www.foxrothschild.com/newspubs/newspubsArticle.aspx?id=4294967686 (last visited April 29,
2012)
19
David Newman, “Accountable Care Organizations and the Medicare Shared Savings Program” Congressional
Research Service (November 4, 2010), pp. 1. (Quoting Aaron McKethan, Mark McClellan, Elliott Fisher, et al.,
Moving from Volume-Driven Medicine Toward Accountable Care, Health Affairs, Health Affairs Blog, August 20,
2009. http://www.healthaffairs.org/blog.) available at http://assets.opencrs.com/rpts/R41474_20101104.pdf .
20
Centers for Medicare & Medicaid Services: Accountable Care Organizations (Last modified 04/05/2012)
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ACO/index.html?redirect=/ACO/ (The ACO
concept envisions multiple providers assuming joint accountability for improving health care quality and slowing
the growth of health care costs. The concept was also included in national health care reform legislation as one of
several demonstration programs to be administered by Medicare (Patient Protection and Affordable Care Act, 2010).
However, ACOs described in health reform legislation are operationally different from other ACO models. The role
of ACOs in integrating and aligning provider incentives in care delivery requires participating organizations to
possess certain key competencies.)
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quality, lower-cost, and better integrated services. 21 Philosophically, the attention of the
health care system changes under ACOs from the traditional focus on treating patients with
truly urgent problems to preventing those conditions in the first place. On the financial
side, ACOs shift away from paying based on the quantity of services rendered and more
toward paying based on the quality of services. 22 Although ACOs may contract with any
payer (Medicare, Medicaid, or private insurer) to provide services and share in any
resulting savings, the results from this shift are assumed to be far reaching and favorable
for the health care delivery system.
As payment for medical services shifts from fee-for-service to more integrated,
bundled charges, health providers will have to work together to provide services in a cost effective manner. For instance, as physicians begin partnering with hospitals and health
providers, hospitals face a very unique challenge of establishing a cost-effective ACO,
conforming to the Medicare Shared Shaving Program criteria, while not losing money. 23
Although big integrated hospital systems and academic medical centers are in the best
position to benefit from the ACO, speculation suggests short term struggles for hospitals
are to be expected. Hospitals will face the difficult task of learning how to cut costs
without losing money which will take time.24 Additionally, asset management firms like

21

Stephen G. Pelletier, ACOs: Controlling Costs While Improving Care, Association of American Medical Colleges
Reporter (February 2011), available at
https://www.aamc.org/newsroom/reporter/feb11/174756/controlling_costs_while_improving_care.html
22
Julie Barnes, The Many Legal Barriers Standing in the way of Health Care Reform, The Atlantic (March 15,
2012, 9:02 AM ET), reprinted in Bipartisan Policy (Posted March 16, 2012), available at
http://www.theatlantic.com/health/archive/2012/03/the-many-legal-barriers-standing-in-the-way-of-health-carereform/254259/
23
Anna Wilde Mathews, Can Accountable-Care Organizations Improve Health Care While Reducing Costs?, Wall
Street Journal (January 23, 2012), available at
http://online.wsj.com/article/SB10001424052970204720204577128901714576054.html
24
Jenny Gold, FAQ on ACOs: Accountable Care Organizations Explained, Kaiser Health News (October 21, 2011),
available at http://www.kaiserhealthnews.org/Stories/2011/January/13/ACO-accountable-care-organizationFAQ.aspx

7

Lazard Asset Management LLC see “managed care, hospitals and post-acute care providers
as the subsectors most impacted by healthcare reform.

Key factors we consider for

companies in these subsectors include health insurance coverage changes, profitability
outlook and potential business model changes as a result of the ACO pilot projects.” 25
ACOs are projected to have a profound impact on other subsectors of the healthcare
industry as well such as pharmaceutical manufacturing. 26 One gap in PPACA was the
inability to create a system for ACOs to limit the patient’s access to cost effective
treatments. Essentially, a provider can create internal rules limiting access to the most cost
effective care, in turn choosing the cheaper of two comparable drugs. 27 In a study by
BioTech Stock Research of United Healthcare’s episodic payment system,
“providers will be more sensitive to cost. If you have two drugs with
similar patient outcomes, the least expensive one will be used ﬁrst. As
we wrote in detail in the April issue of Biotech Monthly, this means
the one used second will still see revenues but lower revenues due to
Label Shift 28 and the Leaky Bucket 29.”30

25

Ross Seidon, U.S. Healthcare Reform: Drivers, Economics and the Supreme Court, Lazard Asset Management
LLC (March 2012), available at http://www.lazardnet.com/confcalls/pdfs/2012/U.S.HealthcareReformDriversEconomics_LazardInsights_201203.pdf
26
Paul H. Keckley, Ph.D, Value-based Purchasing: A Strategic Overview for Healthcare Industry Stakeholders,
Deloitte center for Health Solutions (2011), available at http://www.deloitte.com/assets/DcomUnitedStates/Local%20Assets/Documents/Health%20Reform%20Issues%20Briefs/US_CHS_ValueBasedPurchasin
g_031811.pdf
27
Investment Implications of ACOs & IPAB, Biotech Stock Research Monthly Vol. 11, No. 6 (June 2011), available
at http://www.biotechstockresearch.com/free/v11-n06_IPAB-ACO.pdf
28
“Label Shifting” is the process by which a provider alters the drugs they customary prescribe to a similar less
expensive drug based on external factors
29
Yale economist Arthur Okun famously described the "Leaky Bucket" problem as one in which the mechanisms
necessary to move income from one group to another would inevitably result in losses from, among other things,
administrative costs of government transfer programs. Intuitive picture of a leaking bucket captured the idea that:
government policy and "the market" are opposing forces, with the market poised to do its work if only the
government would get out of the way.
30
Paul H. Keckley, supra note 27
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Under widespread adoption of ACOs, investors are going to have to pay more
attention to pharmaceutical economic analysis and comparative efﬁcacy data. 31 This type of
change makes companies more price-sensitive when pricing their drugs. Researchers
suggest it will take longer for ACOs to adopt new drugs than it currently does because of
questions of cost effectiveness. However, ACOs will not have a drastic effect on the way
the market participants invest in healthcare because they offer too little incentive for
doctors and hospitals to change behavior. With only modest rewards for creating ACOs that
comply with the Shared-Saving Requirements this will not eliminate and may potentially
increase rewards to providers from maintaining current costly practices.32 While shared
savings may entice some providers into new arrangements, it provides a relatively weak
impetus to real change.33 With very small incentives, the change will be extremely slow.

b. Medical Device Tax
When Congress carefully drafted the Affordable Care Act it did so with the intent o f
not adding to the federal budget deficit. 34 To help pay for the expansion of health coverage
to 27 million uninsured Americans, the ACA either reduces Medicare payments or
increases taxes for a wide range of industries that will benefit from health reform
31

Nikolas H. Goldberg; Sebastian Schneeweiss, MD, ScD; Mary K. Kowal, BA; Joshua J. Gagne, PharmD, MS
Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States, JAMA.
2011;305(17):1786-1789, available at http://jama.jamanetwork.com/article.aspx?articleid=899516 “Efficacy
studies are randomized, controlled trials comparing an intervention to a control (often a placebo or a sham
treatment) on a carefully selected group of subjects under controlled conditions. These studies utilizes a variety of
data sources, including systematic reviews of existing literature and analysis of secondary data, such as claims data,
patient registries, and electronic health records.”
32
Anna Wilde Mathews, supra note 23
33
Judy Feder and David Cutler, Achieving Accountable Care and Affordable Care: Key Health Policy Choices to
Move the Health Care System Forward, Center for American Progress (December 2010), available at
http://www.americanprogress.org/wp-content/uploads/issues/2010/12/pdf/affordablecare.pdf
34
Paul N. Van de Water, Excise Tax on Medical Devices Should Not BE Repealed: Industry Lobbyists Distorts
Tax’s Impact, Center on Budget and Policy Priorities (March 11, 2013), available at http://www.cbpp.org/files/214-12health.pdf
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including; hospitals, home health agencies, clinical laboratories, health insurance
providers, drug companies, and manufacturers of medical devices. 35
The ACA imposes a tax equal to 2.3% on the sales price of any taxable medical
device by a medical device manufacturer, producer or importer of such device.36 According
to the Congressional Budget Office (CBO) anticipates that this medical excise tax will
generate $20 billion dollars. 37 The excise tax applies to sales after December 31, 2012. 38 As
such, medical device manufacturers will need to begin accounting for this tax for all sales,
other than tax free sales, beginning January 1, 2013 39 and will need to consider the impact
of this tax on their 2013 results. 40 Medical devices encompass an extremely wide range of
products such as; surgical gloves, dental instruments, wheelchairs, coronary stents,
artificial knees and hips, defibrillators, cardiac pacemakers, irradiation equipment, and
advanced imaging technology. However, the tax does not apply to eyeglasses, contact
lenses, hearing aids, or any other medical device that the public generally buys at retail for
individual use. 41

35

Peter n. Van de Water, supra note 34
Affordable Care Act Tax Provisions, Internal Revenue Service (Last Updated March 19, 2013) available at
http://www.irs.gov/uac/Affordable-Care-Act-Tax-Provisions
37
See Congressional Budget Office, Estimates for the Insurance Coverage Provisions of the Affordable Care Act
Updated for the Recent Supreme Court Decision (July 2012). The ACA comprises the Patient Protection and
Affordable Care Act (Public Law 111-148) and the provisions of the Health Care and Education Reconciliation Act
of 2010 (P.L. 111-152) that are related to health care.
38
Id.
39
Keenan Steiner, Backed By Hatch, Klobuchar, Medical Device Makers Score Victory, Sunlight Foundation
Reporting Group (April 15, 2013),available at http://reporting.sunlightfoundation.com/2013/backed-by-hatchklobuchar-medical-device-makers-score-victory/ (Currently there is a bipartisian effort to repeal the medical device
tax. "Momentum is clearly growing in Congress to repeal the medical device tax as Senators continue to hear from
their constituents that the impact is real.)
40
Price Waterhouse Cooper, Medical Device Excise Tax, Pharmaceutical and Life Sciences Industry Alert (201213), available at http://www.pwc.com/en_US/us/cfodirect/assets/pdf/insight/pls-alert-2012-3-medical-device-excisetax-final.pdf
41
The excise tax is established by section 1405 of the Health Care and Education Reconciliation Act of 2010 (Public
Law 111-152), which effectively substituted for section 9009 of the Patient Protection and Affordable Care Act of
2010 (Public Law 111-148).
36
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In 2011 the Advanced Medical Technology Association (AdvaMed) and FurchtgottRoth Economic Enterprises conducted a study which found that:
"The effect of the tax on earnings of U.S. companies is likely to be
significant. In 2006, medical device manufacturers reported taxable
income of $13.7 billion and paid $3.1 billion in corporate taxes. The
new 2.3 percent excise tax will roughly double their total tax bill and
raise the average effective corporate tax rate to one of the highest
effective tax rates faced by any industry in the world." 42
The U.S. medical device industry has estimated total sales of $106 billion to $116 billion a
year. 43 For example, Johnson and Johnson’s worldwide sales of medical devices and
diagnostics totaled $27 billion in 2012.44 The firm had total sales (on both medical devices
and other products) of $67 billion on which it earned profits of nearly $11 billion. 45 The
effect of the tax on earnings of U.S. companies is likely to reduce their net profits from a
low of 6.8 percent to a high of 40 percent. 46
Although venture capitalist and investors have mixed views on the effectiveness of
the ACA, it seems to be unanimous when it comes to medical devices tax that skepticism is
high and confidence is at an all-time low. In a LinkedIn poll taken from over 550 members
of the Medical Device Group, Medcity News found “35 percent of respondents said they
expected 2013 to be a bad year for the medical device industry, citing problems with
higher-priced devices that provide minimal advantages among areas of concern and lack of
42

Diana Furchtgott-Roth and Harold Furchtgott-Roth, Employment Effects of the New Excise Tax on The Medical
Device Industry (September 2011), available at
http://www.chi.org/uploadedFiles/Industry_at_a_glance/090711EmploymentEffectofTaxonMedicalDeviceIndustryF
INAL.pdf
43
Christopher Flavelle, Medical Device Industry Overstates Tax Impact, Bloomberg Government Study, February 9,
2012.
44
Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results, January 22, 2013, available at
http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=734718
45
Id.
46
Diana Furchtgott-Roth and Harold Furchtgott-Roth, supra note 42
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investments.”47 Exacerbating the lack of confidence, a PricewaterhouseCoopers MoneyTree
Report found that medical device companies received a combined $434 million from 65
deals in the third quarter, which marks a 37 percent drop in dollar amount and a 27 percent
decline in the number of deals from the second quarter. 48 Furthermore, Med Tech Initial
Public Offerings (IPOs) have been virtually non-existent in the past four years which
serves as another indicator of a change in the industry’s health.

Additionally,

PricewaterhouseCoopers also found that Venture Capital Deals were cut in half from 2010
to 2011 from 54 to 22 respectively. 49 Given the amount of innovation of medical devices
that come from smaller companies, that require such capital investments from large players
in the industry or venture capitalist firm, Bill Trainor of Mutual Capital Partners Fund is
confident investors will have to change the way the manage their portfolios. 50

Other

sources, such as Terry McGuire, co-founder of Polaris Venture Partners, explained “the
excise tax is clearly a burden, but hardly a driving factor in investment decisions.” 51
Although there seems to be some optimism for the medical device industry, now is not an
advantageous time to implement such an excise tax. Since the medical industry has been
struggling for the past three years such an excise tax would hinder the flow of capital
investments to medical device manufactures. 52

A study of Universal HealthCare in

Massachusetts provides an example of what might happen nationwide. The reports showed
47

Deanna Pogorelc, The Best and Worst Bets for Healthcare Investing in 2013, MedCity News (December 21,
2012), available at http://medcitynews.com/2012/12/the-best-worst-bets-for-healthcare-investing-in-2013/
48
Venture Capital Investments Decline in Dollars and Deal Volume in Q3 2012, Pricewaterhouse Cooper LLP
(October 19, 2012), http://www.pwc.com/us/en/press-releases/2012/venture-capital-investments-q3-2012-pressrelease.jhtml
49
Matt Dolan, Innovation 101—Technology & Innovation in the Medical Device Industry, Roth Capital Partners
LLC (September 13, 2012), available at
http://www.roth.com/files/marketing/email_blasts/Roth%20Capital%20CONNECT.pdf
50
Pogoreic, supra note 47
51
Dan Primack, Is Obamacare Killing Medical Device Startups?, CNN Money (December 6, 2012),
http://finance.fortune.cnn.com/2012/12/06/is-obamacare-killing-medical-device-startups/
52
Matt Dolan, supra note 49
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that in Massachusetts, 8 out of 9 companies experienced negative comparative growth rates
in Massachusetts as compared to the rest of the US following the implementation of
universal health care in that state.53

Despite the assumption that medical device

manufacturers would benefit from the windfall of formerly uninsured customers now
insured under ACA, there is little data to suggest that such a conclusion after comparing
the average age of a medical device patient (60 years of age) to new insu red customers (45
years of age). 54 Using six case studies, Roth Capital Investments found that trends in
Massachusetts, contrary to an expectation for higher medical device utilization rates,
actually lagged the rest of the US in the years following the legislation of universal health
care. 55
c. Medical Loss Ratio
Another regulation enacted as part of the Affordable Care Act was the imposition of
reporting and rebating requirements upon insurers in order to promote efficiency.
Beginning in August 2012, insurers must report plan costs for the purpose of calculating
their medical loss ratio (the percentage of insurance premium dollars spent on
reimbursement for clinical services and activities to improve healthcare quality). 56 Large
group insurers must spend at least 85 percent of premium dollars on claims and activities to
improve healthcare quality. 57 Individual and small group insurers (those with a total

53

Thomas Sullivan, Affordable Care Act: Medical Device Tax a Problem for Innovation, Policy and Medicine
(November 5, 2012), available at http://www.policymed.com/2012/11/affordable-care-act-medical-device-tax-aproblem-for-innovation.html
54
Matt Dolan, supra note 52
55
Thomas Sullivan, supra note 53
56
Gensina Seiler, Look Out, Look Out: Here Comes Obamacare, 22 No. 1 Wis. Emp. L. Letter 1
57
U.S. Department of Health and Human Services, New Afforbale Care Act rules give consumers better value for
insurance premium, HHS (November 22, 2010), available at
http://www.hhs.gov/news/press/2010pres/11/20101122a.html; see also Medical Loss Ratio: Getting Your Money’s
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average of one to 50 employees based on the preceding calendar year, depending on the
state's definition) must spend at least 80 percent of premium dollars on claims and
activities to improve healthcare quality. 58 This efficiency is measured through the “Medical
Loss Ratio” (MLR), which according to the Act, tracks the percentage of premium dollars
actually expended on health care services or on efforts to improve the quality of health c are
services.59 The ACA requires each insurer to report, on an annual basis, the percentage of
its annual premium receipts that have been applied to medical services or improvements to
medical services. 60 In essence, the medical loss ratio is intended to limit the amount of
overhead that an insurer can carry (and, by implication, profit levels and executive
compensation) by requiring the insurer to rebate to its policyholders and plan participants
any premium revenue in excess of the overhead amount allowed by the Act.

61

Professor Tara Ragone 62 defines the MLR as a calculation where “the numerator of
the ratio containing the insurance company’s expenses related to health care, and the
denominator contains the premiums collected by the insurance company. 63 Which expenses
may be included in the numerator and what adjustments insurers may or must make to the
denominator greatly affect the resulting MLR. Prior to the ACA, some states but not the

Worth on Health Insurance, Healthcare.gov (November 22, 2010), available at
http://www.healthcare.gov/news/factsheets/2010/11/medical-loss-ratio.html
58
Paul J. Routh, Medical Loss Ratio, Welfare Benefits Guide §3:15 (2012)
59
Affordable Care Act's Medical Loss Ratio Provision: Is There A Private Right Of Action?, Thorp Reed Armstrong
LLP (November 15, 2012), available at http://www.martindale.com/insurance-law/article_Thorp-Reed-ArmstrongLLP_1627212.htm
60
U.S. Department of Health and Human Services, supra note 57
61
Affordable Care Act and Medical Loss Ratios, Coventry Healthcare (2012), available at
http://chccarolinas.coventryhealthcare.com/web/groups/public/@cvty_regional_chcnc/documents/webcontent/c0684
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Federal government regulated loss ratios.”64 If an insurance company's MLR falls below
the 80% or 85% threshold, the company must send rebates to the people it insures .65 Not
every state required insurance companies to calculate their MLR, and those that did used
various definitions and formulae for calculating this ratio. 66 However, the new “Medical
Loss Ratio” system is entirely novel in a number of respects: 1) unlike loss ratio regulation
under existing state statutes, the “Medical Loss Ratio” treats administrative expenses
relating to healthcare quality improvement differently from other administrative expenses,
2) rates are reviewed retroactively rather than the prospective review that is the norm under
state rate regulation statutes, 3) the medical loss ratio refunds apply to large group
coverage, which has not generally been subject to rate regulation in the past, and 4) the
medical loss ratio refunds will be computed by broad categories 67 rather than on a productspecific basis. 68 This Federal mandate has led to heavy scrutiny and debate in two specific
areas affecting insurers: (1) brokers' commissions and (2) federal and state taxes.
One of the ways in which some insurers have been cutting their administrative costs
has been by cutting compensation to agents and brokers. According to the Department of
Health and Human Services (HHS) insurance brokers “are independent agents who receive
commissions from an insurer for selling insurance products.” 69 Brokers have many
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important tasks such as (1) help employers design the “right” plan(s) for their employees;
(2) explain the costs and benefits of the plan(s) to the insured; (3) resolve claims-related
problems; and (4) refer customers to health insurance providers, thereby allowing the
insurance companies to limit marketing-related expenses. 70 Specifically, the brokers
expressed concern regarding ACA counting their commissions counted as administrative
expenses in the MLR calculation.

This has been the leading reason why insurers are

already cutting commissions to improve medical loss ratios.” 71 According to a survey by
the National Association of Insurance and Financial Advisors (NAIFA) of “861 of its
members who sell health insurance 70 percent of respondents who sell health insurance
have seen a decrease in commissions since the MLR has gone into effect.”72 Additionally,
state insurance agencies worried that they would be flooded with calls for help if the MLR
pushed too many brokers out of business.73 This reduction of brokers comes at a time
where our economy is at the weakest and millions of health care consumers need the most
help.
With regard to the Federal and State taxes at first glance, the Medical Loss Ratio
may look like a good thing. Allowing insurers to deduct federal and state taxes which apply
to their health insurance coverage from the insurer’s premium revenue is an attractive
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feature of the MLR calculation provision.74 However, this provision may have the opposite
effect on insurers. The significance of the MLR calculation depends on the detail of
calculations. A smaller denominator makes the MLR requirement easier to meet. 75
Therefore, insurance companies naturally want to exclude as many taxes and fees as
possible. However, the drafters of the ACA provided for provisions “that refer[s] only to
Federal taxes and fees that relate specifically to revenue derived from the provision of
health insurance coverage that were included in the ACA.” 76 By allowing less opportunity
to exclude taxes, this relatively narrow definition would make it more difficult for
insurance companies to meet the ACA's minimum MLR requirements. 77 The MLR as
explained has the effect of keeping the carrier's profit down by requiring the carrier to
spend more money in rebates than to the carrier's bottom line.
III.

Investing in Healthcare
a. Quantitative Analysis
Quantitative methods involves a review of the cash flow aspects of the transaction

by employing statistical and mathematical tools that can be used to analyze information in
order to estimate the expect gain or loss of an investment.78 The term quantitative analysis
or research, while distinct, is often confused with qualitative analysis. Although q ualitative
and quantitative research are the two main schools of research and often used in tandem,
quantitative analysis involves assembling statistical information that is absolute such as
74
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numerical records, so that it can be examined in an impartial manner.79 The central theory
behind quantitative analysis is being able to isolated data easier so that they can be counted
and evaluated statistically as well as remove outlying factors that may distract from the
resolution of the inquiry. 80 An analyst generally has a very clear idea what is being
measured before they start measuring it and their study is set up with controls and a very
clear blueprint. The result of quantitative research is a collection of numbers, which can be
subjected to statistical analysis, to come to the end results. This result is what separate
quantitative analysis from other forms which instead describe and analyze an occurrence
using words.
Formulating a financial speculation or hypothesis into a quantitative model allows
analysts to apply statistical analysis to the problem and calculate the probability of certain
outcomes such as, how likely a yield is to increase when a specific action is taken. 81 For
firms seeking to invest in a particular venture, quantitative methods are most commonly
used to value different classes of securities (ie: stocks, bonds, debentures, notes), 82 analyze
criteria for guiding investment decisions, measure risk and asset return, and use statistical
techniques for forecasting. 83
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b. Methods of Valuation
When an event occurs that creates such sweeping reform inevitably there are
winners and losers. The job of analysts is to understand those consequences regardless of
how we feel about the healthcare law. Choosing an investment position in the health care
market is not as simple as purchasing stocks based on news headlines; such strategy is
generally a recipe for disaster. With the healthcare industry soon becoming one of the
largest segments of the United States economy with the massive expansion of insured
individuals, it will be very critical for investors to maintain exposure to it so they can enjoy
robust gains in addition to balanced portfolios. 84
In the view of analysts, valuation is based on fundamentals aimed to give an
estimate of their intrinsic value of a company or its stock based on predictions of the future
cash flows and profitability of the business. 85 In financial markets, valuation is the method
of calculating theoretical values of companies and their stocks. Knowing what an asset is
worth and what determines that value is a pre-requisite for intelligent decision making
when it comes to choosing an investments for a portfolio, in deciding on the appropriate
price to pay or receive, and choosing to finance a business. 86
Analysts use a wide spectrum of models ranging from the simple to the
sophisticated. These quantitative models often make very different assumptions that cannot
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be assessed without analyzing the finances of a company. 87 Each method it in its own way
makes it easier to understand how an investment will fit into the big picture of your
investment scheme. In general terms, there are two approaches to valuation. The first,
Discounted Cash Flow valuation, relates the value of an asset to the present value of
expected future cashflows on that asset. 88 The second, relative valuation, estimates the
value of an asset by looking at the pricing of comparable assets relative to a common
variable like earnings, cashflows, book value or sales. 89
Discounted Cash Flow (DFC) is a valuation method used to estimate the
attractiveness of an investment opportunity by analyzing future free cash flow projections
and discounts the projections to arrive at a present value, which is used to evaluate the
potential for investment. 90 The principle of DCF is that a dollar received today is less
valuable than a dollar received in the future. 91 Therefore, the purpose of a DCF analysis is
to anticipate returns in their present value (PV). 92 This can be accomplished in one of two
ways. They are: Net Present Value (NPV) method and the Internal Rate of Return (IRR)
method.
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DISCOUNTED CASH FLOW
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CF = Cash Flow
r = Discount Rate (calculated by computing Weighted Average Cost of Capital (WACC))

Net present value (net cash flow) is the sum of the initial investment (a negative
cash flow) plus the present values of future cash flows (which may be either negative or
positive).94 If net present value is positive, the investment is profitable and a profit-seeking
investor would pursue it. If the NPV were zero, the investor's assets would not change .
The investment is neither profitable nor unprofitable, and a profit -seeking investor would
be indifferent to it. 95 If the NPV were negative, the financial value of the investor's assets
would be decreased and the investment would not be financially attractive. 96 An investment
that is unprofitable, and a profit-seeking investor would avoid it.97 In summary, NPV or
DCF determines the present dollar value of the future dollar returns and this amount is
compared with the present value of the investment. If the present value of the return is
greater than the present value of the investment, the investment is considered favorable. 98
An Internal Rate of Return (IRR) is a discount rate that makes all future cash
receipts and expenditures equal to the initial cash investment. 99 The use of internal rates of
return permits different investments to be analyzed mathematically to determine which
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ones have the greatest return after considering the time value of money. 100 The IRR is that
discount rate at which the PV of the anticipated total cash inflows is equal to the PV of the
anticipated total cash outflows or the rate at which NPV is zero. 101 IRR is determined
through trial-and-error calculations using a mathematical formula (included with most
spreadsheet programs) or a graph. 102 IRR higher than the minimum acceptable rate of
return, also known as the hurdle rate, indicates a desirable investment project. However, a
project or investment with a lower projected IRR nonetheless may be preferable if that
lower IRR can be earned on a larger principal amount. 103 For example, an opportunity to
earn 30% on a $100,000 investment brings greater absolute rewards than 40% on $1,000. 104
By evaluating the end result of either forms of DCF analysis, one can determine if
an investment is a wise decision. A DCF outcome higher than the current cost of the
investment results in a good investment opportunity. 105
The second method to valuation is by means of relative valuations. These methods
of valuations compare a firm's value to that of its competitors to determine the firm's
financial worth. 106 Relative valuation models are an alternative to absolute value models,
which try to determine a company's intrinsic worth based on its estimated future free cash
flows discounted to their present value. 107 Investors use relative valuation models when
determining whether a company should buy, sell or hold a particular stock or investment
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option.108 These models are designed to take advantage of perceived mispricing among
related financial assets and are often based on “the long-run tendency of market prices to
revert to equilibrium relationships.” 109 The simplest example of a relative value trade
involves identifying a price divergence between two historically related stocks and being
the short position110 of the over-valued stock and the long position 111 on the historically
under-valued stock.112 Valuing securities entails expending efforts to uncover information,
assessing its relevance, and determining the proper quantitative price change that properly
reflects the information. 113
Net Margin
EBITDA Margin
Return on Equity

Consolidated
Medical
Ratio114

Cost

Price Earnings

Book Value
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The main advantage of relative valuation is that it reflects market volatility,
enabling investors to realize at any given moment if it is to their best interest to sell a stock
or to invest building momentum. 115 In addition, relative valuation provides portfolio
managers with a variety of securities that are overvalued or undervalued, thus enabling
them to build more diversified portfolios. 116

IV.

Wall Street’s Response
This paper takes the position that although regulation is needed in order to prevent

fraud, ensure fair competition and to provide affordable health care for all, instituting
specific regulatory action such as the medical device tax creates more complications and
potential harm than potential gains.
Robert Field 117 addresses the similar issue pertaining to governments reoccurring
involvement in the private pharmaceutical industry. 118 The pharmaceutical industry has
grown to be and continuously remains a successful investment because of the ability to
constantly enter the market to replenish the supply. 119

Advocating for government’s

involvement, Field stressed the continually participation was an indispensable catalyst for
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market growth. 120

Without government assistance, the private sector would not have

realized large and robust gains.121 However, there are some clear distinctions that separate
Field’s analysis of the pharmaceutical industry with that of the medical device industry.
Most notably, the government encouraged growth of pharmaceutical discoveries by
offering tax credits to companies conducting research. 122 These tax credits became very
valuable especially for private firms who were reluctant to invest in initial product
development. This cannot be said of the 2.3% medical devise tax. Typically, excise taxes
are used to discourage consumption of potentially dangerous substances, such as tobacco
and alcohol, which might be abused or over consumed if not for the absence of taxation.123
An industry survey discovered 70 percent of device makers thought this tax would have a
negative impact and would result in oppressive compliance measures. 124 When analyzing
financial investment options, investors seek to avail themselves to sufficient returns or
investors will seed their capital elsewhere despite record low interest rates. To see how the
device tax stymies private investment, Forbes analyzed Hill-Rom (“HRC”), a hospital bed
producer.125 Over the past year HRC generated $1,633 million in revenue and earned
$145.1 million of net income. 126 Hill-Rom’s return on equity (“ROE”) totaled 18.6
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percent.127 At 2.3 percent of gross revenue, the device tax knocks net income down to $108
million slashing ROE to 13.7 percent. 128
Another theory Field’s puts forth is the need for governmental presence as a
provider of public trust and confidence in the industry. 129 Political debates over economic
policy commonly pit the virtues of the free market against those of government oversight.
When health care policy is discussed it is normally done so just in the context of the
vacuum that is the health care industry. Policy makers often do not appreciate how the
policies they enact affect the industries around them especially the markets on Wall Street.
Although the medical device industry is known for commitment to shareholder returns with
growth potential from emerging markets and new products,130 quantitative analytics by
performed Wall Street analysts may prove that these new regulations and taxes imposed no
longer make healthcare sub-sectors attractive for investors. In a study co-sponsored by the
National Venture Capital Association (“NVCA”) and the Medical Innovation &
Competitiveness Coalition, 42 percent of venture capital firms planned to make fewer
medical device investments over the next three years and 61 percent of venture capitalist
survey respondents identified regulatory concerns as the most significant factor affecting
their investment decisions. 131
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With the January 2013 passage of the medical device tax, venture capitalists are looking
at prospects for their return-on-investment and now actively factoring in the economic effects of
the excise tax on their prospective clients. The result is that this excise tax is making it difficult
for smaller innovative medical device firms to acquire venture capital necessary to survive and
prosper a determining factor of why the pharmaceutical industry has thrived with government
assistance.132
This unintended effect seems to be counter intuitive to the overall goals of the Affordable
Care Act, which is to cut costs and make healthcare available to all.133 A prime example is the
creations of ACOs which are intended to lower the cost of healthcare by creating incentives to
improve the quality of care.134 However, a penalizing tax on medical devices has a contrary
effect to the cost of healthcare.135 Predictive healthcare, such as a microchip implant that sends
blood chemical results via Bluetooth to predict whether an individual is likely to have a heart
attacks, could be obsolete without such investments in medical device R&D and in the end cost
individual and insurers more money.136 The National Bureau of Economics recently found that
cardiovascular disease costs the United States $110 billion annually.137 In addition, for an
individual who has had a heart attack, the average cost to traditional health insurers for the first
90 days following a heart attack is $38,501.138 Furthermore, Medicare spends over $14,000 per
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patient on hospital bills in the year after a heart attack, plus additional amounts for physicians
and outpatient care. 139
Nevertheless, the greatest source of reassurance for investors is the quality of the
investment themselves. For the medical device tax to have the same effect as government
intervention in the pharmaceutical context, entrepreneurship and innovation need to be the
catalyst for growth.
V.

Conclusion
The health care industry is a sector that strives on free market economics dependent

upon private investments and firm competition. The economic implications stemming from
PPACA may significantly hinder the way our health care industry functions. The 27 taxes
found within in ACA in order to raise revenues for universal health care may prove
debilitating to medical device companies, American patients, and the U.S. economy. As
the market responses to the changes, it is quite likely that many small innovative medical
device companies will not receive the venture capital funding necessary to fund their
devices and thus they will not be able to provide their life sustaining technologies to
patients. The more cognizant policy makers are of capital market trends and conscious of
the quantitative consequence of their decisions, the health care industry may be able to
limit instability within the sector and move toward the overall goals in the Affordable Care
Act.
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